Emcure Pharma and Roche sign agreement to strengthen nephrology and transplant care in India

Mumbai-based Emcure Pharmaceuticals has announced the signing of a distribution agreement with Roche for select products in the nephrology and transplant medicine portfolio.

The agreement marks a significant step toward expanding patient access to critical therapies in chronic kidney disease (CKD), anemia management, and transplant care across India.

Under the agreement, which will be effective April 1, 2026, Emcure will distribute Roche’s established and globally recognised brands in the nephrology and transplant segment in India.

The agreement includes the following brands:

• CellCept®– A globally leading immunosuppressant and original Roche innovation, supporting organ transplants worldwide since 1995.

• Mircera® and Neorecormon®– Proven therapies for anemia in chronic kidney disease, including Mircera’s long-acting ESA with dosing once every 2–4 weeks.

 

Emcure is a market leader in anemia management, and together with its subsidiaries, has a strong presence across nephrology and chronic kidney disease segments. Roche’s nephrology and transplant portfolio strongly complements Emcure’s existing offerings. This strategic alignment enables Emcure to expand its portfolio and bring these important medicines to a wider cross-section of patients across the country.